HK1210424A1 - 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途 - Google Patents

激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途

Info

Publication number
HK1210424A1
HK1210424A1 HK15111246.2A HK15111246A HK1210424A1 HK 1210424 A1 HK1210424 A1 HK 1210424A1 HK 15111246 A HK15111246 A HK 15111246A HK 1210424 A1 HK1210424 A1 HK 1210424A1
Authority
HK
Hong Kong
Prior art keywords
glpir
glp1r
metformin
agonist
diabetes
Prior art date
Application number
HK15111246.2A
Other languages
English (en)
Inventor
．米賈裡
．克拉克
．波裡塞蒂
．小奎達
．瓦爾卡西洛佩茲
．安德魯斯
．戴維斯
．約庫姆
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of HK1210424A1 publication Critical patent/HK1210424A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15111246.2A 2013-01-17 2015-11-13 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途 HK1210424A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (1)

Publication Number Publication Date
HK1210424A1 true HK1210424A1 (zh) 2016-04-22

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111246.2A HK1210424A1 (zh) 2013-01-17 2015-11-13 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途

Country Status (14)

Country Link
US (1) US20150313908A1 (zh)
EP (1) EP2945618B1 (zh)
JP (1) JP6445459B2 (zh)
KR (1) KR102165434B1 (zh)
CN (1) CN104968341B (zh)
AU (1) AU2014207748B2 (zh)
CA (1) CA2896308C (zh)
EA (1) EA201591123A1 (zh)
ES (1) ES2687083T3 (zh)
HK (1) HK1210424A1 (zh)
IL (1) IL239714A0 (zh)
MX (1) MX366685B (zh)
SG (2) SG10201704716XA (zh)
WO (1) WO2014113357A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111108117A (zh) 2017-09-22 2020-05-05 瑞泽恩制药公司 胰高血糖素样肽1受体激动剂及其用途
AU2019266114A1 (en) * 2018-05-08 2020-08-27 Vtv Therapeutics Llc Therapeutic uses of GLP1R agonists
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
EP4130005A4 (en) * 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd CRYSTALLINE FORM A OF GLP-1 RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
NZ587343A (en) * 2008-03-07 2012-05-25 Transtech Pharma Inc Oxadiazoanthracene compounds for the treatment of diabetes
BRPI1013579A2 (pt) 2009-03-30 2020-11-03 Transtech Pharma, Inc. derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
ES2534191T3 (es) * 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Also Published As

Publication number Publication date
EA201591123A1 (ru) 2015-11-30
SG11201504778UA (en) 2015-07-30
CN104968341B (zh) 2020-06-09
WO2014113357A1 (en) 2014-07-24
JP2016505039A (ja) 2016-02-18
CA2896308C (en) 2021-11-09
ES2687083T3 (es) 2018-10-23
KR102165434B1 (ko) 2020-10-14
AU2014207748A1 (en) 2015-07-09
SG10201704716XA (en) 2017-07-28
JP6445459B2 (ja) 2018-12-26
EP2945618A1 (en) 2015-11-25
CN104968341A (zh) 2015-10-07
EP2945618B1 (en) 2018-06-13
MX366685B (es) 2019-07-19
CA2896308A1 (en) 2014-07-24
IL239714A0 (en) 2015-08-31
AU2014207748B2 (en) 2018-10-11
KR20150104572A (ko) 2015-09-15
MX2015008555A (es) 2016-01-22
US20150313908A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
HRP20181296T1 (hr) Novi spojevi za suzbijanje člankonožaca
HK1226084A1 (zh) 用於治療糖尿病的gip和glp-1受體雙重激動劑
IL240285A0 (en) Biomarkers for type ii diabetes and their uses
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
IL239957A0 (en) Assessment, testing and treatment of pkal mediated disorders
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL243572A0 (en) Drug combination for the treatment of melanoma
HK1207860A1 (zh) 用於治療糖尿病及其相關病症的 -苯基- -雜環基-四氫- -吡喃- -胺化合物
GB2519982B (en) Fungicidal composition and the use thereof
HK1210424A1 (zh) 激動劑和二甲雙胍的組合及其在治療 型糖尿病和其他障礙中的用途
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
IL241474B (en) A device with joints for the wrist
PT3041441T (pt) Ortótese da mão para suportar o polegar, em particular nos casos de rizartrose
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
EP3713604C0 (de) Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit
GB201800645D0 (en) Monitoring medication consumption
GB201314183D0 (en) Status of type 2 diabetes
GB201304197D0 (en) Thumb pad embodiments
TWM476976U (en) Wrist pad
GB201320349D0 (en) New therapeutic use
TWM476582U (en) Watch type stethoscope device
GB201303232D0 (en) Tramadol for the mouth